Genetic alterations in pediatric primary brain tumors can be used as diagnostic and prognostic markers and are the basis for the development of new target therapies that, ideally, would be associated with lower mortality and morbidity. | BRAF V600E mutation and 9p21 CDKN2A B and MTAP co-deletions - Markers in the clinical stratification of pediatric gliomas